12.60
+2.7(+27.27%)
Currency In GBp
Address
1 Bartholomew Close
London, EC1A 7BL
United Kingdom of Great Britain and Northern Ireland
Phone
44 20 7206 2650
Website
Sector
Healthcare
Industry
Biotechnology
Employees
5
First IPO Date
October 28, 2003
| Name | Title | Pay | Year Born |
| Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBA | Chairman & Chief Executive Officer | 294,000 | 1956 |
| Dr. Timothy Gary Franklin M.B.A., Ph.D. | Chief Operating Officer & Director | 252,000 | 1964 |
| Ms. Lara E. Sucheston-Campbell | Head of Clinical & Medical Affairs | 0 | N/A |
| Ms. Ashley Louise Clarke A.C.A. | Group Chief Financial Officer & Company Secretary | 0 | N/A |
| Dr. Jean-Marie Geiger PharmD, MD | Head of Clinical Development | 0 | N/A |
| Dr. Laura Mauran-Ambrosino Ph.D. | Chief Scientific Officer of ImmuPharma Biotech | 0 | N/A |
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.